Literature DB >> 9268107

Progressive diaphyseal dysplasia: a three-generation family with markedly variable expressivity.

J M Saraiva1.   

Abstract

Progressive diaphyseal dysplasia was found in a 3-generation family including 18 affected individuals. We describe the clinical and radiographic manifestations in 6 of 18 patients with this autosomal-dominant bone dysplasia and the good symptomatic response to corticosteroid treatment in one of these. The variability of manifestations of the disease in this family and in others previously described seems to depend on the sex of the patient and the parental origin of the mutation. The patients with more severe symptoms are males who inherited an allele of paternal origin. We suggest that the progressive diaphyseal dysplasia gene has a function in endochondral bone formation and that its mutation is a dynamic one with repeat expansion enhanced in father-to-son transmission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268107     DOI: 10.1002/(sici)1096-8628(19970822)71:3<348::aid-ajmg17>3.0.co;2-k

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

1.  Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13.

Authors:  K Janssens; R Gershoni-Baruch; E Van Hul; R Brik; N Guañabens; N Migone; L A Verbruggen; S H Ralston; M Bonduelle; L Van Maldergem; F Vanhoenacker; W Van Hul
Journal:  J Med Genet       Date:  2000-04       Impact factor: 6.318

2.  Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.

Authors:  Giampiero I Baroncelli; Elena Ferretti; Cecilia M Pini; Benedetta Toschi; Rita Consolini; Silvano Bertelloni
Journal:  Mol Syndromol       Date:  2017-09-09

Review 3.  Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment.

Authors:  K Janssens; F Vanhoenacker; M Bonduelle; L Verbruggen; L Van Maldergem; S Ralston; N Guañabens; N Migone; S Wientroub; M T Divizia; C Bergmann; C Bennett; S Simsek; S Melançon; T Cundy; W Van Hul
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

Review 4.  Camurati-Engelmann Disease.

Authors:  Wim Van Hul; Eveline Boudin; Filip M Vanhoenacker; Geert Mortier
Journal:  Calcif Tissue Int       Date:  2019-02-05       Impact factor: 4.333

5.  Camurati-Engelmann disease: imaging, clinical features and differential diagnosis.

Authors:  Aldona Bartuseviciene; Arturas Samuilis; Jovitas Skucas
Journal:  Skeletal Radiol       Date:  2009-02-12       Impact factor: 2.199

6.  Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand.

Authors:  Michael P Whyte; William G Totty; Deborah V Novack; Xiafang Zhang; Deborah Wenkert; Steven Mumm
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

7.  Clinical characteristics and identification of a novel TGFB1 variant in three unrelated Chinese families with Camurati-Engelmann disease.

Authors:  Xiao-Hui Tao; Xing-Guang Yang; Zi-Yuan Wang; Yang Xu; Xiao-Yun Lin; Tian Xu; Zhen-Lin Zhang; Hua Yue
Journal:  Mol Genet Genomic Med       Date:  2022-03-21       Impact factor: 2.473

8.  The first Korean case of Camurati-Engelmann disease (progressive diaphyseal dysplasia) confirmed by TGFB1 gene mutation analysis.

Authors:  Seo-Jin Park; Choon Sik Yoon; Hui-Wan Park; Jong Rak Choi; Jong Shin Chung; Kyung-A Lee
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.